Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice

International Journal of Molecular Medicine

Volumn 30, Issue 1, 2012, Pages 107-113

  Kato, Jun ^a   Koda, Masahiko ^a   Kishina, Manabu ^a   Tokunaga, Shiho ^a   Matono, Tomomitsu ^a   Sugihara, Takaaki ^a   Ueki, Masaru ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Fatty liver Shionogi ob ob mice; Irbesartan; Liver fibrosis; Liver steatosis; Non alcoholic steatohepatitis; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HYDROXYPROLINE; IRBESARTAN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; COLLAGEN TYPE I; DEOXYGUANOSINE; FATTY ACID SYNTHETASE COMPLEX; FATTY LIVER; HEPATIC STELLATE CELLS; INFLAMMATION; LIVER CIRRHOSIS; MALE; MICE; MICE, OBESE; OBESITY; OXIDATIVE STRESS; PPAR ALPHA; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861464460     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.958     Document Type: Article

References (34)

1. Pascale A, Pais R and Ratziu V: An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 19: 415-423, 2010.
2. Hashimoto E and Tokushige K: Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 46 (Suppl 1): S63-S69, 2011.
3. Rector RS, Thyfault JP, Wei Y and Ibdah JA: Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14: 185-192, 2008. (Pubitemid 351314297)
4. Manrique C, Lastra G, Gardner M and Sowers JR: The rennin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 93: 569-582, 2009.
5. De Kloet AD, Krause EG and Woods SC: The renin angiotensin system and the metabolic syndrome. Physiol Behav 100: 525-534, 2010.
6. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K and Adachi M: Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55: 478-488, 2006.
7. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM and Angus PW: Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123: 1667-1676, 2002. (Pubitemid 35231666)
8. Ueki M, Koda M, Yamamoto S, Matsunaga Y and Murawaki Y: Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 41: 996-1004, 2006. (Pubitemid 44741413)
9. El-Demerdash E, Salam OMA, El-Batran SA, Abdallah HM and Shaffie NM: Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats. Clin Exp Pharmacol Physiol 35: 159-167, 2008.
10. Ueki M, Koda M, Matono T, Sugihara T, Maeda K and Murawaki Y: Preventative and therapeutic effects of perindopril on hepatic fibrosis induced by bile duct ligation in rats. Mol Med Rep 2: 857-864, 2009.
11. Ran J, Hirano T and Adachi M: Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 287: E227-E232, 2004. (Pubitemid 38943886)
12. Toblli JE, Muñoz MC, Cao G, Mella J, Pereyra L and Mastai R: ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity 16: 770-776, 2008. (Pubitemid 351465631)
13. Hirose A, Ono M, Saibara T, et al: Angiotension II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45: 1375-1381, 2007. (Pubitemid 46918321)
14. Larter CZ and Yeh MM: Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23: 1635-1648, 2008.
15. Soga M, Kishimoto Y, Kawaguchi J, et al: The FLS mouse: a new inbred strain with spontaneous fatty liver. Lab Anim Sci 49: 269-275, 1999. (Pubitemid 29284381)
16. Soga M, Hashimoto S, Kishimoto Y, Hirasawa T, Makino S and Inagaki S: Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of fatty liver Shionogi (FLS) mice with the Lep(ob) gene. Exp Anim 59: 407-419, 2010.
17. Murawaki Y and Hirayama C: Hepatic collagenolytic cathepsin in patients with chronic liver disease. Clin Chim Acta 108: 121-128, 1980. (Pubitemid 11225070)
18. Wu LL, Chiou CC, Chang PY and Wu JT: Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chem Acta 339: 1-9, 2004. (Pubitemid 37542453)
19. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T and Yoshimatsu H: Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48: 51-57, 2006. (Pubitemid 44297524)
20. Sugimoto K, Qi NR, Kazdová L, Pravence M, Ogihara T and Kurtz TW: Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1003-1009, 2006. (Pubitemid 44297575)
21. Sturzeneker MCS, Ioshii SO, Baroncini LAV and Précoma DB: Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis 216: 97-102, 2011.
22. Ran J, Hirano T and Adachi M: Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab 287: E955-E961, 2004. (Pubitemid 39382933)
23. Matono T, Koda M, Tokunaga S, Kato J, Sugihara T, Ueki M and Murawaki Y: The therapeutic effects of ezetimibe for nonalcoholic steatohepatitis in FLS-ob/ob mice. Hepatol Res 41: 1240-1248, 2011.
24. Nagaya T, Tanaka N, Suzuki T, et al: Down-regulation of SREBP-1c is associated with the development of burned-out NASH. J Hepatol 53: 724-731, 2010.
25. k) rats: a link to amelioration of hypertriglyceridaemia. Br J Pharmacol 160: 1796-1807, 2010.
26. Fernández-Alvarez A, Alvarez MS, Gonzalez R, Cucarella C, Muntané J and Casado M: Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor α (PPARα). J Biol Chem 286: 21466-21477, 2011.
27. Iwai M, Kanno H, Senba I, Nakaoka H, Moritani T and Horiuchi M: Irbesartan increased PPARγ activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem Biophys Res Commun 406: 123-126, 2011.
28. Sharma AM and Staels R: Review: peroxisome proliferator-activated receptor γ and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92: 386-395, 2007.
29. Yoshiji H, Kuriyama S, Yoshii J, et al: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750, 2001. (Pubitemid 32927999)
30. Yoshiji H, Noguchi R, Ikenaka Y, et al: Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes 2: 70, 2009.
31. Fujita K, Yoneda M, Wada K, et al: Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 52: 3455-3464, 2007. (Pubitemid 350077187)
32. Bataller R, Ginès P, Nicolás JM, et al: Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156, 2000. (Pubitemid 30346992)
33. Bataller R, Gäbele E, Parsons CJ, et al: Systemic infusion of angiotensin II exacerbates liver fibrosis in the bile duct-ligated rats. Hepatology 41: 1046-1055, 2005. (Pubitemid 40593912)
34. Kudo H, Yata Y, Takahara T, et al: Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 29: 988-996, 2009.